Medications for Alcohol Use Disorder and Retention in Care in Medicaid-Enrolled Youth, 2014-2019

被引:0
作者
Earlywine, Joel J. [1 ,2 ]
Bagley, Sarah M. [3 ,4 ,5 ,6 ]
Rodean, Jonathan [7 ]
Zima, Bonnie T. [8 ]
Chadi, Nicholas [9 ]
Leslie, Douglas L. [10 ]
Hadland, Scott E. [3 ,4 ,5 ,11 ,12 ,13 ]
机构
[1] Mathematica, Seattle, WA USA
[2] Boston Univ, Sch Publ Hlth, Dept Hlth Law Policy & Management, Boston, MA USA
[3] Boston Med Ctr, Grayken Ctr Addict, Boston, MA USA
[4] Boston Med Ctr, Dept Pediat, Boston, MA USA
[5] Boston Univ, Sch Med, Dept Pediat, Div Gen Pediat, Boston, MA 02118 USA
[6] Boston Univ, Sch Med, Dept Med, Sect Gen Internal Med, Boston, MA USA
[7] Childrens Hosp Assoc, Lenexa, KS USA
[8] Univ Calif Los Angeles, UCLA Semel Inst Neurosci & Human Behav, Los Angeles, CA USA
[9] Univ Montreal, St Justine Univ Hosp Ctr, Dept Paediat, Div Adolescent Med, Montreal, PQ, Canada
[10] Penn State Coll Med, Dept Publ Hlth Sci, Hershey, PA USA
[11] Mass Gen Children, Div Adolescent & Young Adult Med, Boston, MA USA
[12] Harvard Med Sch, Dept Pediat, Boston, MA USA
[13] Mass Gen Children, Div Adolescent & Young Adult Med, 175 Cambridge St, 5th Floor, Boston, MA 02114 USA
关键词
TREATMENT FACILITIES; FAMILY-THERAPY; DEPENDENCE; NALTREXONE; PHARMACOTHERAPIES; ADOLESCENTS; ADULTS; STATES;
D O I
10.1016/j.jadohealth.2023.03.005
中图分类号
B844 [发展心理学(人类心理学)];
学科分类号
040202 ;
摘要
Purpose: Alcohol use disorder (AUD) is a pediatric-onset condition needing timely, effective treatment. Medications for AUD are part of nationally recommended treatments for youth. This study measured receipt of medications and behavioral health services for AUD and subsequent retention in care. Methods: This retrospective cohort study used claims data from > 4.7 million publicly insured youth aged 13-22 years in 15 states from 2014-2019. Timely treatment was defined as receipt of medication (naltrexone, acamprosate, or disulfiram) and/or behavioral health services within 30 days of incident AUD diagnosis. Associations of age and other characteristics with timely treatment were identified using modified Poisson regression. Retention in care (i.e., no period >= 60 days without claims) was studied using Cox regression. Results: Among 14,194 youth with AUD, 10,851 (76.4%) received timely treatment. Only 2.1% of youth received medication (alone or in combination); nearly all (97.9%) received behavioral health services only. Older (aged 16-17 years) and younger adolescents (aged 13-15 years) were 0.13 (95% confidence interval [CI], 0.07-0.26) and 0.24 (95% CI, 0.11-0.51) times as likely, respectively, to receive medications than young adults aged >= 21 years. Median retention in care for youth receiving medications was 119 days (interquartile range, 54-321) compared with 108 days (interquartile range, 43-243) for behavioral health services alone (p = .126). Young adults aged >= 18 years were 1.12 (95% CI, 1.06-1.18) times as likely to discontinue treatment compared with adolescents aged < 18 years. Discussion: This study found that more than seven in 10 youth received AUD treatment but only two in 100 received medications. Future studies should further characterize the effectiveness of medications and determine whether low rates of receipt represent underuse. (c) 2023 Society for Adolescent Health and Medicine. All rights reserved.
引用
收藏
页码:845 / 851
页数:7
相关论文
共 38 条
  • [1] Adolescent-Serving Addiction Treatment Facilities in the United States and the Availability of Medications for Opioid Use Disorder
    Alinsky, Rachel H.
    Hadland, Scott E.
    Matson, Pamela A.
    Cerda, Magdalena
    Saloner, Brendan
    [J]. JOURNAL OF ADOLESCENT HEALTH, 2020, 67 (04) : 542 - 549
  • [2] American Psychiatric Association, 2013, Diagnostic and Statistical Manual of Mental Disorders DSM-5, V5th ed., DOI [10.1176/appi.books.9780890425596, DOI 10.1176/APPI.BOOKS.9780890425596]
  • [3] [Anonymous], 2014, PRINCIPLES ADOLESCEN
  • [4] Combined pharmacotherapies and behavioral interventions for alcohol dependence - The COMBINE study: A randomized controlled trial
    Anton, RF
    O'Malley, SS
    Ciraulo, DA
    Cisler, RA
    Couper, D
    Donovan, DM
    Gastfriend, DR
    Hosking, JD
    Johnson, BA
    LoCastro, JS
    Longabaugh, R
    Mason, BJ
    Mattson, ME
    Miller, WR
    Pettinati, HM
    Randall, CL
    Swift, R
    Weiss, RD
    Williams, LD
    Zweben, A
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (17): : 2003 - 2017
  • [5] Centers for Medicare & Medicaid Services, Reducing substance use disorders: Quality measures
  • [6] Treatment for Nicotine Use Disorder Among Medicaid-Enrolled Adolescents and Young Adults
    Chadi, Nicholas
    Rodean, Jonathan
    Earlywine, Joel J.
    Zima, Bonnie T.
    Bagley, Sarah M.
    Levy, Sharon
    Hadland, Scott E.
    [J]. JAMA PEDIATRICS, 2019, 173 (11) : 1103 - 1105
  • [7] Women and Substance Abuse Problems
    Renée A Cormier
    Colleen Anne Dell
    Nancy Poole
    [J]. BMC Women's Health, 4 (Suppl 1)
  • [8] Naltrexone treatment of adolescent alcoholics: An open-label pilot study
    Deas, D
    May, K
    Randall, C
    Johnson, N
    Anton, R
    [J]. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2005, 15 (05) : 723 - 728
  • [9] Survey of Addiction Specialists' Use of Medications to Treat Alcohol Use Disorder
    Ehrie, Jarrod
    Hartwell, Emily E.
    Morris, Paige E.
    Mark, Tami L.
    Kranzler, Henry R.
    [J]. FRONTIERS IN PSYCHIATRY, 2020, 11
  • [10] Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility
    Fishman, Marc J.
    Winstanley, Erin L.
    Curran, Erin
    Garrett, Shannon
    Subramaniam, Geetha
    [J]. ADDICTION, 2010, 105 (09) : 1669 - 1676